Shares of Heska Corp (NASDAQ:HSKA) have earned a consensus rating of “Buy” from the eight brokerages that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $114.38.
Several equities analysts recently weighed in on HSKA shares. Canaccord Genuity started coverage on shares of Heska in a research report on Thursday, October 5th. They issued a “buy” rating and a $115.00 price target on the stock. Zacks Investment Research cut shares of Heska from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Benchmark reaffirmed a “buy” rating and issued a $120.00 price target (up previously from $106.00) on shares of Heska in a research report on Wednesday, August 9th. B. Riley dropped their price target on shares of Heska from $96.50 to $93.00 and set a “neutral” rating on the stock in a research report on Friday, November 3rd. Finally, BidaskClub cut shares of Heska from a “buy” rating to a “hold” rating in a research report on Monday, August 14th.
In other Heska news, insider Michael J. Mcginley sold 7,826 shares of the stock in a transaction dated Wednesday, November 29th. The shares were sold at an average price of $87.14, for a total value of $681,957.64. Following the completion of the sale, the insider now owns 106,771 shares in the company, valued at approximately $9,304,024.94. The transaction was disclosed in a document filed with the SEC, which is available at this link. 14.70% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the business. Royal Bank of Canada increased its stake in Heska by 96.9% in the 2nd quarter. Royal Bank of Canada now owns 1,014 shares of the medical research company’s stock valued at $103,000 after buying an additional 499 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Heska in the 3rd quarter valued at about $108,000. Victory Capital Management Inc. increased its stake in Heska by 17.5% in the 2nd quarter. Victory Capital Management Inc. now owns 1,133 shares of the medical research company’s stock valued at $116,000 after buying an additional 169 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in Heska in the 2nd quarter valued at about $127,000. Finally, LS Investment Advisors LLC increased its stake in Heska by 411.2% in the 2nd quarter. LS Investment Advisors LLC now owns 1,278 shares of the medical research company’s stock valued at $130,000 after buying an additional 1,028 shares during the last quarter. Hedge funds and other institutional investors own 81.98% of the company’s stock.
Heska (NASDAQ:HSKA) traded down $1.94 during mid-day trading on Friday, hitting $83.00. 79,481 shares of the stock were exchanged, compared to its average volume of 82,358. Heska has a one year low of $66.51 and a one year high of $115.00. The company has a market cap of $622.46, a PE ratio of 44.99, a PEG ratio of 2.29 and a beta of 0.75.
Heska (NASDAQ:HSKA) last announced its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.03. Heska had a net margin of 10.67% and a return on equity of 15.35%. The business had revenue of $31.40 million for the quarter, compared to analysts’ expectations of $36.10 million. During the same quarter last year, the firm earned $0.45 EPS. The firm’s revenue for the quarter was down 6.0% compared to the same quarter last year. research analysts anticipate that Heska will post 2.03 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This article was originally published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://ledgergazette.com/2017/12/06/brokerages-set-heska-corp-hska-price-target-at-114-38.html.
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp and related companies with MarketBeat.com's FREE daily email newsletter.